EGFR and colorectal carcinoma: These data suggest a negative prognostic role of BRAF and KRAS mutation separately in mutational profiling (KRAS, BRAF, NRAS, and PI3KCA) of the EGFR pathway, and the re-sensitization of BRAF- and/or KRAS-mutated CRC has prominent clinical implications.